LMAT Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 11.12%. LeMaitre Vascular's return on equity of 13.37% beat Boston Scientific's return on equity of 8.91%.

LeMaitre Vascular has a consensus price target of --, signalling upside risk potential of 4.09%. On the other hand Boston Scientific has an analysts' consensus of $100.08 which suggests that it could grow by 4.31%. Given that Boston Scientific has higher upside potential than LeMaitre Vascular, analysts believe Boston Scientific is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.965, which suggesting that the stock is 3.494% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.67%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than Boston Scientific quarterly revenues of $4.2B. LeMaitre Vascular's net income of $11.1M is lower than Boston Scientific's net income of $468M. Notably, LeMaitre Vascular's price-to-earnings ratio is 51.86x while Boston Scientific's PE ratio is 79.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 10.09x versus 8.94x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 8.28%. LeMaitre Vascular's return on equity of 13.37% beat Globus Medical's return on equity of 2.27%.

LeMaitre Vascular has a consensus price target of --, signalling upside risk potential of 4.09%. On the other hand Globus Medical has an analysts' consensus of $96.77 which suggests that it could grow by 10.3%. Given that Globus Medical has higher upside potential than LeMaitre Vascular, analysts believe Globus Medical is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.965, which suggesting that the stock is 3.494% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.67%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than Globus Medical quarterly revenues of $625.7M. LeMaitre Vascular's net income of $11.1M is lower than Globus Medical's net income of $51.8M. Notably, LeMaitre Vascular's price-to-earnings ratio is 51.86x while Globus Medical's PE ratio is 129.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 10.09x versus 4.79x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 14.25%. LeMaitre Vascular's return on equity of 13.37% beat Insulet's return on equity of 49.55%.

LeMaitre Vascular has a consensus price target of --, signalling upside risk potential of 4.09%. On the other hand Insulet has an analysts' consensus of $292.08 which suggests that it could grow by 8.03%. Given that Insulet has higher upside potential than LeMaitre Vascular, analysts believe Insulet is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.965, which suggesting that the stock is 3.494% less volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.67%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than Insulet quarterly revenues of $543.9M. LeMaitre Vascular's net income of $11.1M is lower than Insulet's net income of $77.5M. Notably, LeMaitre Vascular's price-to-earnings ratio is 51.86x while Insulet's PE ratio is 46.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 10.09x versus 10.41x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 20.32% compared to LeMaitre Vascular's net margin of 25.43%. LeMaitre Vascular's return on equity of 13.37% beat ResMed's return on equity of 23.76%.

LeMaitre Vascular has a consensus price target of --, signalling upside risk potential of 4.09%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 8.54%. Given that ResMed has higher upside potential than LeMaitre Vascular, analysts believe ResMed is more attractive than LeMaitre Vascular.

LeMaitre Vascular has a beta of 0.965, which suggesting that the stock is 3.494% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

LeMaitre Vascular has a quarterly dividend of $0.16 per share corresponding to a yield of 0.67%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. LeMaitre Vascular pays 41.35% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

LeMaitre Vascular quarterly revenues are $54.8M, which are smaller than ResMed quarterly revenues of $1.2B. LeMaitre Vascular's net income of $11.1M is lower than ResMed's net income of $311.4M. Notably, LeMaitre Vascular's price-to-earnings ratio is 51.86x while ResMed's PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LeMaitre Vascular is 10.09x versus 7.25x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.